Create issue ticket

75 Possible Causes for tillotson

  • Prostatism

    Tillotson, M.D. † , and A. Martin Lerner, M.D. ‡ This article has no abstract; the first 100 words appear below.[]

  • Streptococcus Pneumoniae

    Journal of Clinical Microbiology. 49(1): 400-404 Morrissey, I., Tillotson, G. 2004. Activity of gemifloxacin against Streptococcus pneumoniae and Haemophilus influenzae.[] […] was predetermined until the early 1990’s because the resistance to β-lactam agents was low, therefore penicillin treatment could be relied upon in few cases (Morrissey and Tillotson[] […] in vivo against the respiratory pathogen S. pneumoniae because of its strong affinity for DNA gyrase and topoisomerase IV (the dual target action system) (Morrissey and Tillotson[]

  • Crystalluria

    Ann Pharmacother 26 : 8 –10. 4 Boll P and Tillotson G. ( 1995 ) Tolerability of fluoroquinolone antibiotics.[]

  • Synovial Sarcoma

    Cancer 15: 717–725 PubMed CrossRef Google Scholar Tillotson JF, McDonald JR et al (1951) Synovial sarcomata.[]

  • Angioedema

    Zilberberg MD, Jacobsen T, Tillotson G.[] Zilberberg MD, Nathanson BH, Jacobsen T, Tillotson G. Descriptive epidemiology of hereditary angioedema emergency department visits in the United States, 2006–2007.[]

  • Lomefloxacin

    Ball P, Tillotson G "Tolerability of fluoroquinolone antibiotics: past, present and future." Drug Saf 13 (1996): 343-8 17. Crawford ED, Berger NS, Davis MA, Donohue RE.[]

  • Artemisia Capillaris

    Tillotson A, Tillotson NH. TCM treatment of jaundice. Available online . Yano K. Insect antifeeding phenylacetylenes from growing buds of artemisia capillaris.[]

  • Moxifloxacin

    Iannini PB, Kubin R, Reiter C, Tillotson G "Reassuring safety profile of moxifloxacin." Clin Infect Dis 32 (2001): 1112-4 4. "Product Information.[] Mandell LA, Ball P, Tillotson G "Antimicrobial safety and tolerability: Differences and dilemmas." Clin Infect Dis 32 (2001): s72-9 2. Cerner Multum, Inc.[]

  • Clostridium Infection

    Tillotson currently works for Optimer Pharmaceuticals, Inc.)[] Tillotson used to work for ViroPharma Incorporated and now works for Optimer Pharmaceuticals, Inc., in San Diego, Calif.[] Tillotson used to work for ViroPharma Incorporated.) Rethinking CDI Few other infections have been the subject of so many varied therapeutic approaches.[]

  • Fluoroquinolone

    Ball P, Tillotson G. Tolerability of fluoroquinolone antibiotics. Past, present and future. Drug Saf 1995; 13: 343-58.[]

Further symptoms